Skip to main
EYPT
EYPT logo

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EyePoint Pharmaceuticals (EYPT) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

EyePoint Pharmaceuticals has shown significant progress in its development and commercialization of ophthalmic products, particularly with its recent positive topline results from the Phase 2 VERONA trial of DURAVYU 2.7 mg, which demonstrated substantial improvements in visual acuity and anatomical control. Despite an increase in General and Administrative (G&A) expenses to $52.4 million and Research and Development (R&D) expenses to $132.9 million, the focus on advancing its innovative Durasert E and Verisome technology platforms suggests a commitment to long-term growth and market positioning. Additionally, the company’s geographic expansion across the U.S., China, and the UK, coupled with the recent FDA approvals, indicates a robust foundation for revenue growth and enhanced product offerings in the ophthalmic market.

Bears say

EyePoint Pharmaceuticals has experienced a notable decline in the improvement of best-corrected visual acuity (BCVA) among patients in the high-dose Duravyu cohort between Week 20 and Week 24, indicating potential efficacy concerns. Management acknowledged this drop-off but cited an individual patient’s missed appointment and treatment as an outlier, which raises questions about the overall consistency of treatment results. Furthermore, downward revisions to risk-adjusted projections and price targets have been indicated, reflecting heightened uncertainty regarding the company’s financial outlook.

EyePoint Pharmaceuticals (EYPT) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About EyePoint Pharmaceuticals (EYPT) Forecast

Analysts have given EyePoint Pharmaceuticals (EYPT) a Buy based on their latest research and market trends.

According to 14 analysts, EyePoint Pharmaceuticals (EYPT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

EyePoint Pharmaceuticals (EYPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.